ClinicalTrials.gg
RecruitingNCT07646587SiriusUpdated Oct 23, 2026

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

A Phase 2 interventional study of WIN378 and Placebo in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Windward Bio. Recruiting at 32 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Windward Bio · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 23, 202611 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina — 14 open to participants now, 17 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Argentina.

Planned enrollment
113th of 123
105 · median 872
Started
2026
with 3 others
Phase 2
27 of 131
3 open now
Primary completion
2027-12
later than 5 of 16 live
Registered
129th of 131
by date

Among the 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina, this one is the 113th largest by planned enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 5 of the 16 other live ones, and was the 129th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Pulmonary Disease, Chronic Obstructive with a site in Argentina, or all of them as a file.
02

Study summary

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)

Read the detailed description

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD). Participants will continue their standard background COPD therapy. Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Respiratory Disease
  • Monoclonal Antibody
  • Inflammation
  • TSLP
  • Moderate - Severe
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 40 to 80 years
  • Post-BD spirometry at screening /FVC \< 0.70 and FEV1 30-80% predicted
  • On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
  • Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
  • Elevated eosinophil count
  • Weight/ within allowed range

Exclusion criteria

Exclusion Criteria:

  • pulmonary disease other than (COPD)
  • Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
  • Clinically significant cardiovascular disease
  • Recent respiratory infection or COPD exacerbation
  • Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life
  • Pregnancy or breastfeeding
  • Smoking or diagnosed substance use disorder
  • Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    WIN378 Dose 1

    WIN378 SC injections will be administered

    Drug: WIN378

  • Experimental
    WIN378 Dose 2

    WIN378 SC injections will be administered

    Drug: WIN378

  • Experimental
    Placebo

    Placebo SC injections will be administered

    Drug: Placebo

Interventions

  • DrugWIN378

    WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval

  • DrugPlacebo

    Placebo matching WIN378

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AEs)

    Time frame: Week 0 - Week 36

  2. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Week 0 - Week 36

  3. Change from baseline in systolic blood pressure (mmHg)

    Time frame: Week 0 - Week 36

  4. Change from baseline in diastolic blood pressure (mmHg)

    Time frame: Week 0 - Week 36

  5. Change from baseline in pulse rate (beats/minute)

    Time frame: Week 0 - Week 36

  6. Change from baseline in respiratory rate (breaths/minute)

    Time frame: Week 0 - Week 36

  7. Change from baseline in oxygen saturation (%)

    Time frame: Week 0 - Week 36

  8. Change from baseline in body weight (kg)

    Time frame: Week 0 - Week 36

  9. Change from baseline in body mass index (kg/m^2)

    Time frame: Week 0 - Week 36

  10. Change from baseline in body temperature (°C)

    Time frame: Week 0- Week 36

  11. Change from baseline in clinical chemistry laboratory assessments

    Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.

    Time frame: Week 0 - Week 36

  12. Change from baseline in haematology laboratory parameters

    Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count

    Time frame: Week 0 - Week 36

  13. Change from baseline in coagulation laboratory parameters

    Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen

    Time frame: Week 0 - Week 36

  14. Change from baseline in urinalysis parameters

    Urinalysis assessments will include protein, pH, blood, glucose and leucocytes

    Time frame: Week 0 - Week 36

  15. Change from baseline in electrocardiogram QT interval

    Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)

    Time frame: Week 0 - Week 36

  16. WIN378 Serum concentration (PK)

    Time frame: Week 0 to week 36

Secondary outcomes

  1. Change from baseline in Blood Eosinophil Count

    Time frame: Week 0 to Week 24

  2. Change in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: Week 0 to Week 24

  3. Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Week 0 to Week 24

  4. Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)

    Time frame: Week 0 to Week 24

  5. Incidence and magnitude of anti-drug antibodies to WIN 378

    Time frame: Week 0 to Week 36

07

Study locations

32 of 32 sites recruiting
  • WB Contracted Clinical Research Site
    Los Angeles, California 93534, United States
    Recruiting
  • WB Contracted Clinical Research Site
    Jacksonville, Florida 32209, United States
    Recruiting
  • WB Contracted Clinical Research Site
    Miami Lakes, Florida 33014, United States
    Recruiting
  • WB Contracted Clinical Research Site
    North Dartmouth, Massachusetts 02747, United States
    Recruiting
  • WB Contracted Clinical Research Site
    Charlotte, North Carolina 28277, United States
    Recruiting
  • WB Contracted Clinical Research Site
    Medford, Oregon 97504, United States
    Recruiting
  • WB Contracted Clinical Research Site
    DuBois, Pennsylvania 15801, United States
    Recruiting
  • WB Contracted Clinical Research Site
    McKinney, Texas 75069, United States
    Recruiting
  • WB Contracted Clinical Research Site
    Waxahachie, Texas 75165, United States
    Recruiting
  • WB Contracted Clinical Research Site
    Bahía Blanca, Buenos Aires B8000JRB, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires 2035, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C1012AAR, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C1023AAB, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C1028AAP, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C1122AAK, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C1425BEN, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C1425FVH, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires C142ABP, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Quilmes, Buenos Aires B1878DVB, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires F.D. C1414AIF, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Buenos Aires F.D. C1426ABP, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Córdoba, Córdoba Province X5000DCE, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Buenos Aires, Mendoza Province M5500AXR, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Mendoza, Mendoza Province 5501, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Mendoza, Mendoza Province M5500CBA, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Rosario, Santa Fe Province S2000DBS, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Rosario, Santa Fe Province S2000KZD, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Rosario, Santa Fe Province S2013OJN, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    Santa Fe, Santa Fe Province S3000ASF, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    San Miguel de Tucumán, Tucumán Province T4000CBC, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    San Miguel de Tucumán, Tucumán Province T4000IAP, Argentina
    Recruiting
  • WB Contracted Clinical Research Site
    San Miguel de Tucumán, Tucumán Province T4000IFL, Argentina
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 18 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 12, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Dec 17, 2027
CompletionEst.
Jan 7, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added
Show 11 added (10 Argentina, 1 United States)
  • WB Contracted Clinical Research Site · Jacksonville, United States
  • WB Contracted Clinical Research Site · Bahía Blanca, Argentina
  • WB Contracted Clinical Research Site · Buenos Aires, Argentina
  • WB Contracted Clinical Research Site · Buenos Aires, Argentina
  • WB Contracted Clinical Research Site · Quilmes, Argentina
  • WB Contracted Clinical Research Site · Córdoba, Argentina
  • WB Contracted Clinical Research Site · Mendoza, Argentina
  • WB Contracted Clinical Research Site · Rosario, Argentina
  • WB Contracted Clinical Research Site · San Miguel de Tucumán, Argentina
  • WB Contracted Clinical Research Site · San Miguel de Tucumán, Argentina
  • WB Contracted Clinical Research Site · San Miguel de Tucumán, Argentina
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    11 sites added
    Show 11 added (10 Argentina, 1 United States)
    • WB Contracted Clinical Research Site · Jacksonville, United States
    • WB Contracted Clinical Research Site · Bahía Blanca, Argentina
    • WB Contracted Clinical Research Site · Buenos Aires, Argentina
    • WB Contracted Clinical Research Site · Buenos Aires, Argentina
    • WB Contracted Clinical Research Site · Quilmes, Argentina
    • WB Contracted Clinical Research Site · Córdoba, Argentina
    • WB Contracted Clinical Research Site · Mendoza, Argentina
    • WB Contracted Clinical Research Site · Rosario, Argentina
    • WB Contracted Clinical Research Site · San Miguel de Tucumán, Argentina
    • WB Contracted Clinical Research Site · San Miguel de Tucumán, Argentina
    • WB Contracted Clinical Research Site · San Miguel de Tucumán, Argentina
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646587
Lead sponsor
Windward Bio
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jun 2, 2026
Primary completion
Dec 17, 2027 (estimated)
Completion
Jan 7, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Juliana Hutchinson, MSc
Contact
clinical.trial.enquiry@windwardbio.com
+4161 551 75 75
Omar Khwaja, MD
study director · Windward Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion